CRYSTAL FORM A OF FEXUPRAZAN HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present application provides a crystal A of fexuprazan hydrochloride. An X-ray powder diffraction pattern thereof has characteristic peaks at positions of 2θvalues of 9.1±0.2°, 13.7±0.2°, 14.9±0.2° and 18.3±0.2°, and has a characteristic peak at at least one position of 2θ values of 8.2±0.2°, 12.3±0.2°, 17.9±0.2°, 20.1±0.2°, 21.0±0.2°, 21.5±0.2°, 22.7±0.2°, 23.0±0.2°, 24.9±0.2°, 25.7±0.2°, 28.0±0.2° and 28.9±0.2°. A preparation method for the crystal A is simple and convenient with good reproducibility, and the crystal A has low requirements for the preparation process and the storage condition, and exhibits good physicochemical stability under the open conditions of 25 °C/60% RH, 40 °C/75% RH and room temperature/92.5% RH. Particularly, compared with a known crystal form I of the fexuprazan hydrochloride, the crystal form A has better chemical stability; and the crystal form A is in the shape of a short rod of less than or equal to 100 μm (more preferably 20-50 μm), and the crystal form A is not prone to